B. Riley restated their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a report published on Tuesday morning, Zacks.com reports. B. Riley also issued estimates for TG Therapeutics’ Q2 2019 earnings at ($0.38) EPS, Q3 2019 earnings at ($0.34) EPS, Q4 2019 earnings at ($0.32) EPS, FY2019 earnings at ($1.41) EPS, FY2020 earnings at ($1.26) EPS, FY2021 earnings at ($0.96) EPS, FY2022 earnings at ($0.63) EPS and FY2023 earnings at $0.24 EPS.
A number of other brokerages also recently issued reports on TGTX. BidaskClub upgraded shares of TG Therapeutics from a hold rating to a buy rating in a report on Friday, March 1st. ValuEngine upgraded shares of TG Therapeutics from a sell rating to a hold rating in a report on Friday, March 29th. Cantor Fitzgerald initiated coverage on shares of TG Therapeutics in a report on Friday, March 29th. They set an overweight rating and a $17.00 price target for the company. Zacks Investment Research downgraded shares of TG Therapeutics from a buy rating to a hold rating in a report on Saturday, April 6th. Finally, HC Wainwright reiterated a buy rating and issued a $20.00 target price on shares of TG Therapeutics in a report on Friday, April 12th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. TG Therapeutics currently has an average rating of Buy and an average price target of $14.07.
Shares of NASDAQ TGTX opened at $7.26 on Tuesday. The company has a quick ratio of 1.72, a current ratio of 1.72 and a debt-to-equity ratio of 1.89. TG Therapeutics has a 1 year low of $3.32 and a 1 year high of $14.65.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.01. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 99,471.43% and a negative return on equity of 309.17%. As a group, research analysts expect that TG Therapeutics will post -1.61 EPS for the current year.
Institutional investors have recently bought and sold shares of the stock. LPL Financial LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $49,000. NumerixS Investment Technologies Inc acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $50,000. Ladenburg Thalmann Financial Services Inc. increased its holdings in TG Therapeutics by 46.5% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,927 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 2,200 shares during the last quarter. National Asset Management Inc. acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $58,000. Finally, Stifel Financial Corp acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $59,000. Hedge funds and other institutional investors own 54.60% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Recommended Story: Producer Price Index (PPI)
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.